IL264961A - - Google Patents

Info

Publication number
IL264961A
IL264961A IL26496119A IL26496119A IL264961A IL 264961 A IL264961 A IL 264961A IL 26496119 A IL26496119 A IL 26496119A IL 26496119 A IL26496119 A IL 26496119A IL 264961 A IL264961 A IL 264961A
Authority
IL
Israel
Application number
IL26496119A
Other languages
English (en)
Other versions
IL264961B1 (en
IL264961B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL264961A publication Critical patent/IL264961A/en
Publication of IL264961B1 publication Critical patent/IL264961B1/en
Publication of IL264961B2 publication Critical patent/IL264961B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL264961A 2016-08-23 2017-08-22 Antibodies against VEGF–A and their uses IL264961B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378391P 2016-08-23 2016-08-23
PCT/EP2017/071106 WO2018037001A1 (en) 2016-08-23 2017-08-22 Anti-vegf-a antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL264961A true IL264961A (enExample) 2019-04-30
IL264961B1 IL264961B1 (en) 2024-10-01
IL264961B2 IL264961B2 (en) 2025-02-01

Family

ID=59677248

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264961A IL264961B2 (en) 2016-08-23 2017-08-22 Antibodies against VEGF–A and their uses

Country Status (9)

Country Link
US (2) US10919958B2 (enExample)
EP (2) EP3783022B1 (enExample)
JP (2) JP6949106B2 (enExample)
KR (1) KR102538827B1 (enExample)
CN (1) CN109863172B (enExample)
AU (2) AU2017315076B2 (enExample)
ES (2) ES3071579T3 (enExample)
IL (1) IL264961B2 (enExample)
WO (1) WO2018037001A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485273B2 (ja) * 2020-06-25 2024-05-16 国立大学法人 鹿児島大学 抗ｖｅｇｆ－ａ抗体による癌に対する治療応答性を予測又は決定するための方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CN104231078A (zh) * 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
CA2666974A1 (en) * 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
JP5425180B2 (ja) * 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102276722B (zh) * 2011-01-14 2013-05-08 中国科学院北京基因组研究所 新型血管内皮生长因子人源化单克隆抗体
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途

Also Published As

Publication number Publication date
EP3783022A3 (en) 2021-06-30
US20210147531A1 (en) 2021-05-20
CN109863172A (zh) 2019-06-07
EP3783022B1 (en) 2026-03-04
JP2019528074A (ja) 2019-10-10
US10919958B2 (en) 2021-02-16
IL264961B1 (en) 2024-10-01
ES3071579T3 (en) 2026-06-24
KR102538827B1 (ko) 2023-05-31
CN109863172B (zh) 2022-08-26
CA3034576A1 (en) 2018-03-01
JP7277531B2 (ja) 2023-05-19
WO2018037001A1 (en) 2018-03-01
AU2020289850B2 (en) 2024-06-06
EP3504236B1 (en) 2020-09-23
US20190202903A1 (en) 2019-07-04
JP2022008447A (ja) 2022-01-13
JP6949106B2 (ja) 2021-10-13
AU2017315076B2 (en) 2020-10-08
AU2017315076A1 (en) 2019-04-04
US11634483B2 (en) 2023-04-25
IL264961B2 (en) 2025-02-01
AU2020289850A1 (en) 2021-01-28
EP3783022A2 (en) 2021-02-24
ES2836286T3 (es) 2021-06-24
EP3504236A1 (en) 2019-07-03
KR20190040029A (ko) 2019-04-16

Similar Documents

Publication Publication Date Title
BR112018068177A2 (enExample)
BR112019002665A2 (enExample)
BR112018004986A2 (enExample)
BR112019001429A2 (enExample)
BR212018070320U2 (enExample)
BR102017004441A2 (enExample)
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019003296B1 (pt) Método para acionamento automático de um modo atrasado direto
BR112019001236B1 (pt) Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa
BR112019001623B1 (pt) Kit de ensaio de ligação ao ligante para detectar a presença de giberelinas em uma amostra
BR112018074347B1 (pt) Método realizado por um sistema operacional de host sendo executado em um dispositivo de host, e dispositivo
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019013609B1 (pt) Método e aparelho de processamento de informação de mídia de streaming
BR112019006736A2 (enExample)
CN303647767S (zh) 舞台监督专用操作台
CN303638534S (zh) 茶具
CN303539512S (zh) 包装桶(1)
CN303536045S (zh) 嫁衣（15）
CN303536047S (zh) 嫁衣（14）
CN303613185S (zh) 玩具(切切乐-12)
CN303535545S (zh) 冰棒(北冰熊脆皮雪糕冰棒)
CN303536110S (zh) 眼罩（花纹）